Notice:  Some Mac users have reported difficulty viewing this website with Safari or Firefox.  Please use Internet Explorer until I can get the problem with my source code corrected.


   1954 and Now      David F. Colvard, M.D.
                                                                              Diplomate of the American Board of Psychiatry & Neurology       

Dr. Colvard received his medical degree and psychiatric training at Duke University Medical Center. He is a board-certified psychiatrist and certified physician investigator and has been in the private practice of psychiatry in Raleigh since 1983.  He specializes in the diagnosis and treatment of  older adolescents and adults (16 to 64 years old) with depression, bipolar disorder, obsessive-compulsive disorder, anxiety disorders, marital-sexual problems (ethics),  adjustment disorders, and other psychiatric conditions.  He has been a clinical research investigator in several psychiatric medication trials and scuba diving panic and anxiety and safety.  Dr. Colvard writes the weekly column "A Shrink Studies Scuba" for The Bonaire Reporter.


Dr. Colvard does NOT provide evaluations or treatment for alcohol or substance abuse/dependence, dual diagnosis, personality disorders, or chronic pain. 

Dr. Colvard also does NOT provide evaluations for child custody or domestic violence.


Disclaimer:  The content of this website, and any services contained therein, is not intended to, and does not, provide medical advice, diagnosis, or treatment.  Any communication with the physician through this website does not establish a physician-patient relationship.


Dr. Colvard's Private Practice of Psychiatry

NOTICE OF PRIVACY PRACTICES (Microsoft Word Format)

Intake Form for New Patients (Microsoft Word Format)

Daily Mood Diary (pdf)

Consent Form for Release of Patient Information (Microsoft Word Format)

(Maps to LabCorp Patient Service Centers for lab tests)

Office Address: 3725 National Drive, Suite 228, Glenwood Place, Raleigh, NC 27612

Office and Appointment Phone Number: 919-781-3141

Emergency Number: 919-831-5537

Email to Dr. Colvard's Office

Office Hours by appointment only: Monday - Thursday 8AM-5PM; Friday 8AM-3PM

Full charges will be made for appointments not cancelled 24 hours in advance.

Full payment* is expected at the time of service.


Insurance:  Dr. Colvard is a Blue Cross Blue Shield North Carolina PPO Provider.  *Co-payment is expected at the time of service.   Check the back of your card for preauthorization requirements.  Not all services or diagnoses are covered by BCBS, so check your plan provisions before calling to schedule an appointment.  Dr. Colvard does NOT participate in the HMO-Blue Care plan.

Until further notice, Dr. Colvard is NOT accepting any new patients whose out-patient treatment requires pre-authorization or approval by Magellan Health Services, including BCBS of Texas and BCBS Federal Employee Plan members.

Dr. Colvard does NOT participate in or accept any other insurance plan or managed care plan; including MedCost, United Health Care, United Behavioral Health, CIGNA, CIGNA Behavioral Health, Magellan Health Services, Medicare, Medicaid, Tricare, or any other  insurance plan or managed care plan. 

Dr. Colvard has opted out of Medicare and Tricare and no claims for his services may be filed with Medicare or any Medicare supplemental carrier or Tricare.


Hows Your Health logo

Your Personalized Guide to the
Best Health Care and Medical Care...

it's easy, confidential, and it works!


Directions to Office: From Crabtree Valley I-440 and Glenwood Ave (NC-70) interchange, head east on Glenwood Avenue towards downtown. At the top of the first hill turn left at the stop light onto Woman's Club Drive into the Glenwood Place Office Center. Woman's Club Drive merges into National Drive and 3725 National Drive Northampton Building is on the left. The office is on the 2nd floor in Suite 228.


  Curriculum Vitae

Publication  - A Study of Panic in Recreational Scuba Divers  (PDF download)                        (co-authored with Lynn Y. Colvard)                    The Undersea Journal (First Quarter 2003)

Publication - On a Pill and a Prayer   (PDF download)                                                        (co-authored with William P. Wilson)                        Christian Counseling Today (Fall 1995)


Disclaimer:  The content of this website, and any services contained therein, is not intended to, and does not, provide medical advice, diagnosis, or treatment.  Any communication with the physician through this website does not establish a physician-patient relationship.


Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Class Suicidality Labeling Language for Antidepressants

“All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Such observation would generally include at least weekly face-to-face contact with patients or their family members or caregivers during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may be appropriate between face-to-face visits.

Adults with MDD or co-morbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.”

Revised 1/26/05


 

www.dbsalliance.org


 

www.adaa.org

Self Tests of Anxiety Disorders 


 

OC Foundation

www.ocfoundation.org


 

Panic Attacks Anxieties Anxiety Attacks OCD Social Anxiety Disorder

www.anxieties.com

 R. Reid Wilson, Ph.D., Chapel Hill, NC

A free internet self-help site for persons suffering from anxiety, panic attacks, phobias, obsessive-compulsive disorder - OCD, fear of flying and post-traumatic stress disorder - PTSD.  Extensive information and skills, plus the latest on helpful medications.

 


www.ptsdalliance.org

The Posttraumatic Stress Disorder (PTSD) Alliance is a group of professional and advocacy organizations that have joined forces to provide educational resources to individuals diagnosed with PTSD and their loved ones; those at risk for developing PTSD; and medical, healthcare and other frontline professionals.


National Institute of Mental Health (NIMH)

Mental Health Topics



Toastmasters may be the most cost-effective "treatment"

for Social Phobia or Social Anxiety.



Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
 
A. John Rush, M.D., Madhukar H. Trivedi, M.D., Stephen R. Wisniewski, Ph.D., Jonathan W. Stewart, M.D., Andrew A. Nierenberg, M.D., Michael E. Thase, M.D., Louise Ritz, M.B.A., Melanie M. Biggs, Ph.D., Diane Warden, Ph.D., M.B.A., James F. Luther, M.A., Kathy Shores-Wilson, Ph.D., George Niederehe, Ph.D., Maurizio Fava, M.D., for the STAR*D Study Team (NEJM 354: 1231-1242)  March 23, 2006
 
Conclusions After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression.

(ClinicalTrials.gov number, NCT00021528 [ClinicalTrials.gov] .)

The New England Journal of Medicine is owned, published, and copyrighted © 2006 Massachusetts Medical Society. All rights reserved.


Medication Augmentation after the Failure of SSRIs for Depression

Madhukar H. Trivedi, M.D., Maurizio Fava, M.D., Stephen R. Wisniewski, Ph.D., Michael E. Thase, M.D., Frederick Quitkin, M.D., Diane Warden, Ph.D., M.B.A., Louise Ritz, M.B.A., Andrew A. Nierenberg, M.D., Barry D. Lebowitz, Ph.D., Melanie M. Biggs, Ph.D., James F. Luther, M.A., Kathy Shores-Wilson, Ph.D., A. John Rush, M.D., for the STAR*D Study Team (NEJM 354: 1243-1252)  March 23, 2006

Conclusions Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings. Augmentation with sustained-release bupropion does have certain advantages, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events.

(ClinicalTrials.gov number, NCT00021528 [ClinicalTrials.gov] .)

The New England Journal of Medicine is owned, published, and copyrighted © 2006 Massachusetts Medical Society. All rights reserved.


God's Yellow Pages

- Let your fingers do the walking thru the Bible


Disclaimer:  The content of this website, and any services contained therein, is not intended to, and does not, provide medical advice, diagnosis, or treatment.  Any communication with the physician through this website does not establish a physician-patient relationship.


Return to Home Page

Bonaire Studio Condominium Rentals

DivePsych.com (Scuba and Psych)

David's Underwater Photos

 

[Hit Counter]

 Since 25 January 2007

© Copyright 2000-2007 David F Colvard, M.D. All Rights Reserved.  All Material provided in this website is provided for educational purposes only. Consult your own physician regarding the applicability of any opinions or recommendations with respect to your symptoms or medical condition.